Literature DB >> 16580736

CD28 and ICOS: similar or separate costimulators of T cells?

Miranda E A T van Berkel1, Mariëtte A Oosterwegel.   

Abstract

Numerous studies have revealed that the B7.1/B7.2-CD28 and B7RP-1-ICOS (Inducible COStimulator) pathways provide crucial costimulatory signals to T cells. We have compared the contribution of these pathways during primary and effector responses, in vitro and in vivo, molecularly as well as functionally. This comparison between CD28 an ICOS after initiation of T cell activation demonstrates that both CD28 and ICOS function similarly during expansion, survival and differentiation of T cells and that both CD28 and ICOS are necessary for proper IgG responses. The major differences between CD28 and ICOS are differences in expression of both receptors and ligands, and the fact that CD28 induces IL-2 production, whereas ICOS does not. In addition, ICOS is more potent in the induction of IL-10 production, a cytokine important for suppressive function of T regulatory cells. All data available at present indicate that both molecules are very suitable candidates for immunotherapy, each in their own unique way.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580736     DOI: 10.1016/j.imlet.2006.02.007

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  26 in total

1.  Antigen presentation and MHC class II expression by human esophageal epithelial cells: role in eosinophilic esophagitis.

Authors:  Daniel J Mulder; Aman Pooni; Nanette Mak; David J Hurlbut; Sameh Basta; Christopher J Justinich
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Antigen-independent adhesion and cell spreading by inducible costimulator engagement inhibits T cell migration in a PI-3K-dependent manner.

Authors:  Jennifer L Franko; Alan D Levine
Journal:  J Leukoc Biol       Date:  2008-12-18       Impact factor: 4.962

3.  Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.

Authors:  Johnson Q Tran; Marcus O Muench; Rachael P Jackman
Journal:  Blood Adv       Date:  2020-11-10

Review 4.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

Review 5.  Targeting inhibitory pathways in cancer immunotherapy.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Curr Opin Immunol       Date:  2010-05-12       Impact factor: 7.486

6.  Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol.

Authors:  Haitian Lu; Barbara L F Kaplan; Thitirat Ngaotepprutaram; Norbert E Kaminski
Journal:  J Leukoc Biol       Date:  2008-11-06       Impact factor: 4.962

7.  Re-annotation is an essential step in systems biology modeling of functional genomics data.

Authors:  Bart H J van den Berg; Fiona M McCarthy; Susan J Lamont; Shane C Burgess
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

8.  Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.

Authors:  Simon Voelkl; Tamson V Moore; Michael Rehli; Michael I Nishimura; Andreas Mackensen; Karin Fischer
Journal:  Cancer Immunol Immunother       Date:  2008-10-03       Impact factor: 6.968

9.  ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival.

Authors:  Omid Akbari; Philippe Stock; Everett H Meyer; Gordon J Freeman; Arlene H Sharpe; Dale T Umetsu; Rosemarie H DeKruyff
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

10.  Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection.

Authors:  Ellen Marks; Martina Verolin; Anneli Stensson; Nils Lycke
Journal:  Infect Immun       Date:  2007-07-16       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.